KINinactive
Kindred Biosciences, Inc.
Biopharma developer (SEC filing verified)·Phase 3·CEO: Richard Chin, M.D.
ImmunologyDermatology
Run Kindred Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Kindred Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Governance
Frequently asked questions
Who is the CEO of Kindred Biosciences, Inc.?
Richard Chin, M.D. is the chief executive officer of Kindred Biosciences, Inc. (KIN).
What therapeutic areas does Kindred Biosciences, Inc. focus on?
Kindred Biosciences, Inc. develops therapies across Immunology, Dermatology.
923 companies304,844 SEC filings22,644 clinical trials100% citation-verification pass rate (7d)How we verify →
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.